GlassScriptPhysician profile
Arthur Tsai
NPI 1679638423
$4,352.51
in general payments reported to CMS, 2019-2025
29 companies · $687 in 2025
The $687 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $466 · 2021: $952 · 2022: $695 · 2023: $567 · 2024: $705 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.37 |
| Education | $290.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $737.67 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $512.68 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $427.40 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $403.37 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $243.20 | 2019-2023 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $237.96 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $209.50 | 2022-2025 | Tarpeyo |
| Amgen INC. | $174.62 | 2019-2025 | Tavneos, Krystexxa |
| Ardelyx, INC. | $158.40 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $155.90 | 2024-2025 | Ozempic, Wegovy |
| Travere Therapeutics, INC. | $142.56 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $113.09 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.58 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $104.64 | 2019-2022 | |
| Daiichi Sankyo INC. | $97.77 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $92.77 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $79.74 | 2022-2024 | Lupkynis |
| Alnylam Pharmaceuticals INC. | $66.20 | 2021 | |
| Alexion Pharmaceuticals, INC. | $54.38 | 2019-2025 | Ultomiris |
| Mallinckrodt Enterprises LLC | $28.93 | 2019 | |
| Horizon Therapeutics Plc | $28.59 | 2020 | |
| Renalytix Ai, INC. | $28.53 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Pharmacosmos Therapeutics INC. | $25.56 | 2021 | |
| Apellis Pharmaceuticals, INC. | $25.00 | 2025 | |
| Mallinckrodt Hospital Products INC. | $21.40 | 2020 | |
| Lilly USA, LLC | $21.05 | 2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $20.47 | 2020 | |
| Scpharmaceuticals INC. | $17.75 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.80 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.